Introduction
The importance of insulin-like growth factor-I receptor (IGF-IR) action in breast cancer has been clearly demonstrated. Its expression has been observed in 87% of breast cancer specimens (Peyrat et al., 1990) , and overexpressed IGF-IR in human tumor specimens is functional, having increased kinase activity compared to normal mammary tissue (Resnik et al., 1998) . Furthermore, Cullen and colleagues (Cullen et al., 1990; Singer et al., 1995) have shown that breast cancer evolution is associated with the induction of IGF-II secretion, another IGF-IR ligand, from stromal cells neighboring malignant breast tissue. Butler et al. (1998) have shown that systemically administered IGF-I stimulates tumor growth in mice in a dose-dependent fashion using NIH 3T3 cells overexpressing IGF-IR. Inhibition of IGF-IR activity by overexpression of a dominant-negative form of IGF-IR in MDA-MB-231 and MDA-MB-435 breast cancer cell lines inhibits the adhesion, invasion, and metastasis of these cells, as well as enhances their sensitivity to Taxol-induced cell death (Dunn et al., 1998) . Some of these IGF-IR-mediated tumorigenic properties may be attributed to its central role in the regulation of proteins important for either matrix attachment or cell survival.
Activated IGF-IR imparts both survival and proliferative effects in various experimental models including neuronal and cancer cells. After IGF-IR autophosphorylation, IGF-IR complexes with and tyrosine phosphorylates IRS docking proteins which then activate second messengers, such as mitogen-activated protein kinase (MAPK), also known as extracellular signal-related kinase (ERK) and PI 3-kinase. Recently, many significant observations have been published regarding the role of serine/threonine kinases that phosphorylate IRS-1. Interestingly, serine phosphorylation of IRS-1 by downstream kinases can regulate IRS-1 tyrosine phosphorylation status and its ability to serve as a substrate to insulin receptor (IR) or IGF-IR. Based on IRS-1's sequence, there are 35 potential serine/ threonine phosphorylation sites. Some of these sites, when phosphorylated, result in either sustained or abbreviated IRS tyrosine phosphorylation, modifying downstream responses in a positive or negative fashion. Activation of pathways involving PI 3-kinase, Akt, GSK3 (glycogen synthase kinase-3), MAPK, and c-Jun N-terminal kinase (JNK) (among others) is known to serine phosphorylate various IRS-1 sites and presumably the duration of IGF-I or insulin signaling. Further, IRS-1 signaling may be mediated by proteasome degradation subsequent to ligand binding; this activity is also mediated through PI 3-kinase but not MAPK (Lee et al., 2000) .
Soon after PI 3-kinase activity is enhanced by binding to IRS-1, activation of downstream kinases Akt and/or p70 S6 kinase occurs. PI 3-kinase activation of Akt conveys many growth-factor-dependent survival effects (Kennedy et al., 1997) . Enhanced Akt activity results in inhibition of many cell death proteins through phosphorylation of BAD (BCL-X L /BCL-2 associated death promoter) (Datta et al., 1997) , the protease caspase-9 (Cardone et al., 1998) , and the forkhead transcription factor family (Brunet et al., 1999) .
In addition to inducing PI 3-kinase-dependent responses, IGF-I also strongly activates MAPK in MCF-7 and T47D breast cancer cells. MAPK inhibition by the pharmacologic agent PD0908059 reduces proliferation of MCF-7 and T47D cells, thus implicating a role for MAPK in IGF-I-mediated proliferation (Hermanto et al., 2000) . Another MAPK family protein that is also activated by IGF-I is JNK (Monno et al., 2000) ; however, the function of this activation is poorly understood. In fact, others have shown that IGF-I pretreatment inhibits JNK activity induced by tumor necrosis factor-a (TNFa), and anisomycin in 293 cells (Okubo et al., 1998) . Since JNK is activated by diverse cell stimuli, including stress, growth factors (i.e. epidermal growth factor (EGF)), and cytokines (i.e. TNFa and interleukin-1) (Sluss et al., 1994; Whitmarsh et al., 1995; Rosette and Karin, 1996) , JNK-mediated effects can be proapoptotic, proliferative, or antiproliferative.
JNK is best characterized by its sensitivity to stress treatments like anisomycin, irradiation, and TNFa. Many chemotherapy drugs also induce JNK as a result of DNA damage or microtubule interference. In particular, microtubule-interfering agents (MIAs), such as paclitaxel (Taxol) and docetaxel (Taxotere), activate JNK through pathways involving Ras and ASK1 apoptosis signal-regulating kinase-1 (Chen et al., 1996; Wang et al., 1998) , indicating that activation of JNK is needed to initiate the microtubular disarray caused by MIAs. Thus, there is considerable evidence to support the role of JNK in regulating apoptosis following cellular stress. When JNK activity is enhanced by chemotherapeutic agents and radiation, it signals cells to undergo programmed cell death (Chen et al., 1996; Wang et al., 1998) .
In this study, we investigated the mechanism(s) of IGF-I survival responses in chemotherapy-treated breast cancer cells. We focused on JNK activation by the MIA, Taxol, and sought to determine if this activation might be altered by IGF-I cotreatment in breast cancer cells. We initially hypothesized that IGF-IR chemoprotective effects in our model result from stimulation of PI 3-kinase and its downstream effector, Akt. Here, we confirm that Akt has a significant role in IGF-I-mediated survival; however, we also show that IGF-I treatment alone potently activates JNK in breast cancer cell lines. In MCF-7 cells, but not in T47D cells, this action is significantly reduced by PI 3-kinase inhibition. Cotreatment of breast cancer cells with Taxol and IGF-I results in an additive increase in JNK activity. The resulting cellular outcome of JNK overexpression is attenuation of IGF-I responses. These inhibitory effects of JNK on IGF-I responses appear to result from phosphorylation of human Ser 312 (corresponding to rat Ser 307 ) on IRS-1. Altogether, these results suggest that IGF-I may downregulate its own survival effects via activation of JNK, thus abrogating its ability to promote cell survival or proliferation.
Materials and methods

Cell culture and treatments
MCF-7 cells were provided by C Kent Osborne (San Antonio, TX, USA) and T47D cells were obtained from the University of Colorado Cancer Center, Tissue Culture Core (Denver, CO, USA). Both cell lines were maintained in full media improved minimal essential medium (IMEM) with phenol red (Mediatech, Herndon, VA, USA) supplemented with 10% fetal bovine serum (Gemini, Calabasas, CA, USA), antibiotics, glutamine, and insulin. In each experiment, cells were plated in full media and cultured overnight at 371C and 5% CO 2 . The following day, cells were washed twice with warm phosphatebuffered saline (PBS, Biofluids, Rockville, MD, USA) and then cultured overnight in serum-free media (SFM). The next day, cells were treated with IGF-I (Bioreclamation, Hicksville, NY, USA and the National Hormone and Pituitary Program obtained from NHPP, NIDDK and Dr AF Parlow), Taxol (paclitaxel (Mead Johnson, Princeton, NJ, USA)), or Taxotere (docetaxel (Rhone-Poulenc Rorer Pharmaceuticals, Collegeville, PA, USA)) as described in figure legends. Pretreatments with either 100 nm wortmannin or 50-100 mm LY294002 as indicated (Calbiochem and Alexis Biochemicals, respectively, San Diego, CA, USA) were performed 40 min prior to stimulation with IGF-I. All protein concentrations from cell extracts were determined using a Bio-Rad D/C protein assay kit (Bio-Rad, Hercules, CA, USA).
Transfection experiments
Hemagglutinin (HA)-tagged Akt and Akt (K179A, kinase dead) vectors were graciously provided by ME Greenberg (Datta et al., 1997) . The myr-HA-Akt pcDNA3 construct was a gift from JR Testa (Mitsuuchi et al., 2000) . JNK and JNK (T183A/Y185F, kinase dead) pcDNA3 constructs were obtained from C Franklin, University of Colorado Health Sciences Center. Generation of both wild-type (Wt) and mutant (Mt) Akt and JNK stable transfectants was performed by plating 2 Â 10 6 of MCF-7 cells per 10 cm dish. The following day, cells were transfected with 10 mg of DNA by lipofection (Lipofectaminet, Gibco BRL, Grand Island, NY, USA). Control cells were transfected with empty vector. After 24-48 h, cells were selected with 800 mg/ml of G418. Individual resistant colonies were isolated and expanded. Detection of clones overexpressing either Akt and JNK Wt or Mt genes was performed by Western blot analysis using HA-probe (F-7) primary antibody (sc-7392, Santa Cruz Biotechnology, Santa Cruz, CA, USA). For transient transfections, 1.8 Â 10 6 MCF-7 cells were plated in 60 mm dishes. The next day, cells were transfected using Lipofectaminet and Plust reagent according to product(s) instructions (Gibco BRL, Grand Island, NY, USA). Cells were then placed in SFM overnight prior to treatment.
JNK assay and Western blot analysis
As a positive control for JNK activation, cells were plated and serum-starved as described previously. UV irradiation was performed by exposing cells to UVC (ultraviolet-C, 50 J/m 2 ) in a Strategene UV linker 1800 (Stratagene, La Jolla, CA, USA). Cells were then incubated at 371C in 5% CO 2 for 50 min before preparing cell lysates. Other cells were plated and serumstarved and then exposed to either IGF-I and/or chemotherapy as indicated. Tissue culture dishes were washed twice with ice-cold PBS. Cells were harvested and in vitro kinase assays were performed as described previously (Hibi et al., 1993) using cell lysate volumes corresponding to 400-600 mg of total protein. The products were then resolved by 10% SDS-PAGE (polyacrylamide gel electrophoresis). The gel was dried and subjected to radiography. Additionally, phosphorylated c-jun product incorporating 32 P was quantitated by PhosphorImager analysis.
To assure that kinase reactions in each experiment contained approximately equal amounts of JNK protein per sample, 10 ml of supernatant from each kinase reaction was run on a 10% SDS-PAGE. Proteins were transferred to Immobilon-P transfer membrane (Millipore, Bedford, MA, USA) and JNK protein quantity was verified by immunoblotting with JNK1 antibody (FL, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and enhanced chemiluminescence (Amersham, Piscataway, NJ, USA).
Akt substrate construct, affinity purification, immobilized and soluble GST thrombin-Akt substrate
The peptide RPRAATF, corresponding to the sequence containing the threonine phosphorylation site of GSK-3, was fused in frame with GST in pGEX-4T-1 by first hybridizing the oligonucleotides (5 0 -AATTGCGTCCGCGTGCTGCCACC-TTCG-3 0 ) and (5 0 -AATTCGAAGGTGGCAGCACGCGGA-CGC-3 0 ) to produce a double-stranded DNA with EcoRI sticky ends. This DNA fragment was then cloned into the EcoRI site of pGEX-4T-1 (Pharmacia Biotech, Piscataway, NJ, USA), regenerating only one EcoRI site. A construct with the insert in the correct orientation was identified by restriction analysis and sequencing (University of Colorado Cancer Center DNA Sequencing Core Service). Affinity purification of the GST thrombin-Akt substrate fusion protein was performed as described by Smith and Johnson (1988) .
Akt assay
After IGF-I treatment, tissue culture dishes were washed twice with ice-cold PBS. Cells were harvested in lysis buffer and kinase assays performed, as previously described (Franke et al., 1995) , using volumes of precleared lysate containing 400 mg of total protein for each sample. Reactions were terminated with 15 ml of 4 Â sample buffer. The products were then resolved by 10% SDS-PAGE. The gel was dried and subjected to radiography. Additionally, phosphorylated product incorporating 32 P was quantitated by PhosphorImager analysis. Immunoprecipitation or Western blot analysis of Akt1 was performed using anti-Akt1 antibody (C20, Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Apoptosis assays
A total of 75 000 MCF-7 cells were plated in each 1.7 cm 2 chamber of Biocoat CultureSlidest (Falcon, Becton Dickinson Labware, Franklin Lakes, NJ, USA). Cells were cultured overnight as described above. The following day, cells were washed twice with PBS and then exposed to SFM control, IGF-I 50 ng/ml alone, Taxol 0.02 mm alone, or Taxol plus IGF-I as described in figure legends. At 48 h after exposure to treatment cells were fixed in 3% formaldehyde in PBS for 5 min, washed three times with PBS, and nuclei were stained with a solution containing 15 mm Hoechst 33258 in PBS for 10 min. A minimum of 200 cells were counted per treatment and the nuclei morphology determined as viable or apoptotic using a fluorescence microscope (Zeiss, Oberkochen, Germany).
Poly(ADP) ribose polymerase (PARP) cleavage was measured in cells transiently transfected (see above) with myr-HAAkt-pcDNA3 or empty pcDNA3 vector. Additionally, PARP experiments using overexpressed JNK were from the stably transfected MCF-7 cells. Cells were treated as described above and lysed using EB buffer (20 mm Tris-HCl, pH 7.6, 0.25 m NaCl, 3 mm EDTA, 0.5% IGEPAL CA-630 with freshly added 1 mm DTT (dithiothreitol), 1 mm phenylmethylsulfonyl fluoride (PMSF), 20 mg/ml aprotinin, 5 mg/ml leupeptin, and 2 mm Na orthovanadate). A total of 70 mg of protein was then resolved by 10% SDS-PAGE. Proteins were transferred to nitrocellulose and Western blots performed using anti-PARP antibody (H250, sc-7150, Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Anchorage-independent growth assays (AIG)
Parental MCF-7 or MCF-7 stable transfectants of Wt or Mt JNK were suspended in 5% charcoal stripped serum (css) (7IGF-I) and 0.4% SeaPlaque agarose (BioWhittaker Molecular Applications, East Rutherford, NJ, USA) at a density of 15 Â 10 3 cells/35 mm dish. Cell suspensions were overlayed on a solidified bottom layer of 5% CSS and 0.6% SeaPlaque agarose and then incubated for 10 days at 371C. Each group was assayed in triplicate dishes. On day 10, colonies equaling approximately X20 cells were counted.
IRS-1 immunoprecipitation and Western blot analysis
Nontransfected and transfected cells were treated with IGF-I (50 ng/ml) and/or LY294006 (50 mm) according to figure legends. Cells were transfected with either empty vector or pEBG-JNK1 (a gift from Dr Kyriakis, Harvard University) according to the method described above. Following culture and/or transfection, cells were serum-starved overnight prior to treatment. Following treatment, cell lysates containing 300 mg of protein were incubated with 2.4 mg of anti-IRS-1 antibody (Upstate Biotechnology, Lake Placid, NY, USA) and 30 mg of rProtein G Agarose beads (Gibco, Gaithersburg, MD, USA) overnight at 41C. Beads were washed three times in lysis buffer and resuspended in sample buffer. Samples were loaded on a 7% SDS-PAGE acrylamide gel, then transferred to nitrocellulose. Membranes were blocked in 5% milk in TBST, then incubated with either antiphospho-IRS-1(Ser 307 ) (Upstate Biotechnology, Lake Placid, NY, USA) or an antiphosphotyrosine antibody (RC20, BD Transduction, San Diego, CA, USA). All Western blots were analysed using enhanced chemiluminescence according to the manufacturer's instructions (Amersham, Piscataway, NJ, USA).
Data analysis
Apoptosis assays were analysed by multiple logistic regression performed using SAS/PROC GENMOD, version 6.12 (SAS Institute, Carey, NC, USA). Tests were performed for overall effect of IGF-I or the transfected gene on Taxol-induced apoptosis, as well as for significant interaction effects between IGF-I and the transfected gene. As multiple comparisons were required to address all questions of interest, results were not considered statistically significant unless the contrast reached Po0.005.
Results
MIA treatment activates JNK in breast cancer cells
The various biological outcomes of IGF-I treatment of breast cancer cells have been well described. However, less is known about the signaling pathways that allow IGF-I to convey its cytoprotective effects in chemotherapy-treated cancer cells. We initially set out to measure JNK response to chemotherapy in our model, and then to determine if IGF-I treatment might suppress stressrelated signaling as a possible mechanism for its inhibition of programmed cell death. JNK activation in response to chemotherapy treatment has been suggested to correspond to cell sensitivity to chemotherapy (Potapova et al., 1995) . Therefore, we tested if the chemotherapeutic agents, doxorubicin, Taxol, and Taxotere, induce JNK activity in MCF-7 breast cancer cells. Treated cells were harvested at various time points to determine the peak time of activation. Figure 1 illustrates that Taxol and Taxotere treatment of cells induced JNK activity approximately threefold, while JNK activation by doxorubicin is somewhat less than threefold. A bimodal pattern of JNK activation was observed with Taxol treatment, with early activation occurring at 2 h of exposure and maximal activation observed at 8 h. Taxotere treatment led to similar levels of JNK induction as Taxol (Xthreefold over control), however only one peak activation time occurred at 2 h of exposure.
IGF-I induces JNK via PI 3-kinase in MCF-7 cells
In order to study IGF-I's ability to regulate JNK in breast cancer cells, we measured the effect of IGF-I treatment alone on JNK activity. Initially, we predicted that IGF-I treatment alone would either (1) suppress JNK signaling, since many treatments that stimulate JNK result in cell death and IGF-I opposes this response or (2) have minimal effect on JNK, as other investigators have shown that tyrosine kinase receptor activation leads to low levels of JNK activity, generally peaking within 30 min of exposure (Kyriakas et al., 1994; Westwick et al., 1994; Fanger et al., 1997; Goedert et al., 1997; Alblas et al., 1998) . Figure 2 shows that IGF-I potently stimulates JNK in both MCF-7 and T47D breast cancer cells. Maximal JNK activity was observed in MCF-7 cells after 2 h of exposure, when approximately a ninefold level of induction was typically observed in multiple experiments with MCF-7 cells; this JNK induction was notably more robust activation than what we observed with the chemotherapy agents. In T47D cells (Figure 2 ), JNK activation peaked at 30 min and was somewhat less than that observed in MCF-7 cells. Since PI 3-kinase is a known second messenger for IGF-IR signaling, we sought to then determine if IGF-I activation of JNK is PI 3-kinase dependent. Addition of the PI 3-kinase inhibitors, wortmannin and LY294002, to IGF-I-treated MCF-7 cells significantly reduced IGF-I-dependent activation of JNK (Figure 3) . Although IGF-I induced JNK activity in both breast cancer cell lines, use of both PI 3-kinase inhibitors showed that IGF-I activation of JNK was PI 3-kinase dependent in MCF-7 cells but not in T47D cells (Figure 3 ). These data support the hypothesis that PI 3-kinase lies upstream of JNK in MCF-7 cells treated with IGF-I and suggest that IGF-I activation of JNK through PI 3-kinase may influence IGF-I and/or Akt survival responses.
Combined IGF-I and MIA treatment results in an additive JNK response
We then assessed endogenous JNK response to cotreatment using IGF-I and chemotherapy to determine if these two treatments might counteract one another's signaling through JNK. UV treatment was also studied in cotreatment of cells to ascertain if IGF-I effects on JNK agonists could be extended to other stress treatments. MCF-7 cells were pretreated with either Taxol (for 5-7 h) or Taxotere (for 1 h), then IGF-I was added for the last hour of exposure, in order to harvest cells at the approximate times of maximal activity for each treatment. Figure 4a and b shows JNK phosphorylation of c-Jun substrate under the conditions described above. In contrast to a previous report (Okubo et al., 1998) and our predictions, IGF-I cotreatment of cells did not interfere with JNK activation by other JNKactivating agents. In fact, JNK induction was higher with cotreatment when IGF-I was added after stress treatment (Figure 4 ) or simultaneously (data not shown). The greatest JNK activity was observed when cells were treated for the duration of time seen for maximal activity with each treatment alone. These conclusions can be extended to other stress treatments that induce JNK activity like Taxotere and UV ( Figure  4c and d) . Western blots assessing total JNK protein in kinase reactions confirm that changes in JNK activity are not a result of changes in the amount of JNK protein in the various samples. Because of the large increase in JNK activity induced by UV, significant increases with IGF-I cotreatment were more difficult to observe. Since cotreatment with IGF-I and chemotherapy led to an increase in JNK activity, we sought to determine if this activation is reduced by PI 3-kinase inhibition. Wortmannin inhibited JNK activity in IGF-I treated samples (Figure 4a and b) . These data show that both stress treatment and IGF-I treatment enhance JNK activity and indicate that IGF-I survival responses may be mediated in a complex manner involving both JNK and Akt activation. JNK activation by both stress and growth factor treatment may also indicate complex signaling through different isoforms, resulting in different biological responses (Potapova et al., 2000; Chen et al., 2001; She et al., 2002) . Next, we set out to characterize the roles of IGF-I-activated JNK and Akt on cellular outcome(s).
Akt, but not JNK, enhances IGF-I cytoprotection
First, we needed to confirm that Akt is activated by IGF-I treatment in MCF-7 cells. We developed a kinasespecific substrate using the Akt consensus binding sequence of GSK (a well-characterized Akt substrate) to investigate the involvement of downstream Akt activity in PI 3-kinase-dependent survival in our model. In vitro kinase assays confirmed that IGF-I treatment of MCF-7 cells induced Akt maximally at 10 min of exposure ( Figure 5a ) and that pretreatment with the PI 3-kinase inhibitors, LY294002 (Figure 5b ) or wortmannin (data not shown), reduced IGF-I induction of Akt. Increased Akt activity was observed both when Akt was isolated by immunoprecipitation (data not shown), and when Akt-containing cell lysates were exposed to an immobilized Akt-specific substrate, GST-GSK, following IGF-I treatment. These results support that PI 3-kinase and Akt may elicit IGF-I survival effects in MCF-7 cells. In T47D cells, Akt is phosphorylated even in the absence of growth factor indicating that PI 3-kinase activity may be constitutive in that cell line (data not shown).
In order to more clearly decipher the potential role of either JNK or Akt in IGF-I cytoprotection, MCF-7 cells were stably transfected with either Wt Akt, Wt JNK, Mt Akt (K179A, kinase dead), or Mt JNK (T183A/Y185F, kinase dead) HA-tagged constructs. Stable transfectants were plated in chamber slides, serum-starved overnight, and treated cells were exposed to Taxol or IGF-I treatment alone or in combination. Figure 6a shows that IGF-I significantly reduced apoptosis induced by Taxol (test for overall effect, Po0.0001). IGF-I reduced cell death in parental and Mt Akt-transfected cells by 59 and 53%, respectively, compared to Taxol treatment alone. Cells overexpressing Wt Akt experienced a 34% reduction in apoptosis with IGF-I treatment (P ¼ 0.056). The lack of a significant effect of IGF-I on Wt Akt-expressing cells appears to be because of the dramatic effect that overexpression of Wt Akt has on Taxol's ability to induce apoptosis in these cells. Wt Akt overexpressing cells underwent 70% less apoptosis than parental MCF-7s treated with Taxol alone (13 versus 44%, Po0.0001). We did not observe a significant difference between Mt Akt transfectants and parental cells with respect to IGF-I protection from Taxolinduced apoptosis. These latter results suggest either that another IGF-I-dependent pathway may counteract Mt Akt effects or that Mt Akt overexpression was not able to squelch endogenous Akt signaling in response to IGF-I.
Cells transfected with Wt or Mt JNK were treated in a similar fashion as described above (Figure 6b ). Overall, parental control groups were very similar to those in Akt experiments; in JNK experiments, IGF-I reduced Taxol-induced apoptosis in parental cells by 60 versus 59% in Akt experiments (Figure 6a and b) . Comparison
IGF-I
-3min 3min 5min 5min LY --+ -+ Fold change: 1.0 2.8 1.9 2.9 1. GST-Akt peptide substrate is phosphorylated by IGF-I-treated MCF-7 cell lysates. GST-Akt-specific substrate (GST-GSK) was developed as described in Materials and methods. (a) MCF-7 cells were treated with IGF-I 50 ng/ml and at the indicated times as described in Materials and methods. Phosphorylated GST-GSK product resulting from in vitro kinase assays was detected and measured. The graph shown represents three independent experiments (mean7s.e.m.). (b) MCF-7 cells were either preincubated in 50 mm LY294002 (LY) for 40 min prior to IGF-I treatment or treated with IGF-I alone, as indicated. Phosphorylated GST-GSK was analysed using SDS-PAGE and autoradiography of all treatment groups of Wt JNK transfectants to parental cells demonstrates that overexpression of Wt JNK results in a significant increase in apoptosis (test for overall effect, P ¼ 0.0001). Figure 6b also shows that, similar to the effects of Wt Akt, transfection of cells with Mt JNK leads to a dramatic decrease in cell sensitivity to Taxol compared to parental cells, 19 versus 47% apoptosis (P ¼ 0.0009). This lends further support to the hypothesis that JNK activity is transducing a cell death signal under cellular stress. Similar to the Wt Akttransfected cells, we did not observe significant increases in protection with Mt JNK overexpression when cells were cotreated with IGF-I.
Since the Hoechst apoptosis assay may be somewhat subjective, significant results were confirmed using PARP cleavage analysis using separate stable transfectant lines, shown in Figure 7 . Using this assay, parental MCF-7 cells underwent apoptosis, as indicated by the appearance of a PARP cleavage fragment at 85 kDa, when treated with Taxol. Again, IGF-I protected from Taxol-induced PARP cleavage at Taxol concentrations up to 0.04 mm (Figure 7a) . To clarify the role of Akt in our model, we inhibited PI 3-kinase using LY294002, and we also determined the contribution of activated Akt in a fashion that eliminates other IGF-I-and PI 3-kinase-dependent pathways by using the myristylated form of Akt (myr-Akt) in transient transfections.
Preincubation of MCF-7 cells with LY294002 enhanced Taxol-mediated PARP cleavage and inhibited IGF-I protection of cells (Figure 7b ), while overexpression of myr-Akt blocked Taxol-induced apoptosis (Figure 7c ), confirming that Akt mediates cell survival in Taxoltreated cells. However, data including the LY294002 compound must be interpreted with caution since this agent also inhibits JNK in our model. In contrast to these Akt data, overexpression of Wt JNK alone enhanced Taxol-induced PARP cleavage (Figure 7d) . Further, using the Wt JNK transfectants we were still unable to demonstrate that JNK activation by IGF-I had any effect on cell survival. These observations may be explained either by the lack of a role for JNK in conveying an IGF-I survival responses or by a dominant effect of Taxol-induced JNK. The last possibility, which we were unable to ascertain in these studies, is the presence of JNK isoform responses that may be treatment dependent.
JNK inhibits MCF-7 AIG
We have previously established that IGF-I treatment of MCF-7 cells enhances AIG (Van Den Berg et al., 1997) . In order to determine if IGF-I induction of JNK results in a change in IGF-I-mediated responses in the absence of a strong stress treatment, we assessed the effect of JNK overexpression on IGF-I-enhanced colony formation (Figure 8 ). Stable transfectants of Wt and Mt JNK were compared to parental MCF-7 cells. Wt JNK overexpression alone strongly inhibited MCF-7 colony formation (comparing parental MCF-7 cells to Wt JNK transfectants), and it also blocked IGF-I enhancement of colony formation (comparing Wt JNK transfectants to Wt JNK transfectants + IGF-I), suggesting that JNK activation by IGF-I antagonizes IGF-I tumorigenic effects. Both Mt JNK transfectant samples, cultured in 5% CSS and 5% CSS + IGF-I treatment, formed increased numbers of colonies that were similar to the parental MCF-7, IGF-I-treated controls. These data support the conclusion that IGF-I induction of JNK is inhibiting IGF-I proliferative or survival effects in MCF-7 cells.
Phosphorylation of IRS-1 human Ser 312 is PI 3-kinasedependent and increased in Wt JNK transfectants Given our evidence that JNK inhibits IGF-I responses and that of other investigators showing that JNK can bind to IRS-1 and serine phosphorylate rat Ser 307 (human Ser 312 ), we decided to determine if this response could be a potential mechanism for the observed inhibitory effect of JNK by IGF-I treatment in our cells. Parental MCF-7 cells were pretreated with LY294002 in some instances prior to treating the cells with IGF-I or Taxol. Total IRS-1 was immunoprecipitated, and isolated protein was analysed using a rat IRS-1 antibody Ser 307 (corresponding to human Ser
312
) for Western blot analysis. Figure 9a shows that IGF-I treatment of parental MCF-7 cells enhances phosphorylation of Ser 312 at times where peak JNK activation by IGF-I was observed in these cells. Further, this activity was blocked by inhibiting PI 3-kinase with LY294002. Taxol treatment also increased Ser 312 phosphorylation (Figure 9b ), indicating that JNK may be mediating phosphorylation of this serine site. In Figure 9c , cells were transfected using either empty vector or a GST-Wt JNK containing plasmid. After serum starvation, transfected cells were treated with IGF-I and LY294002 as described above. IRS-1 was immunoprecipitated from cleared cell lysates using a total IRS-1 antibody. Western blot analysis was performed using the rat Ser 307 IRS-1 antibody. Again, IGF-I treatment of cells enhanced Ser 312 (rat Ser 307 ) phosphorylation and LY294002 pretreatment inhibited IGF-I-dependent serine phosphorylation. In these experiments, an increase in IGF-I-mediated serine phosphorylation was observed in the Wt JNK transfectants compared to mocked transfected cells. Further, pretreatment with LY294002 inhibited serine phosphorylation in both mock and Wt JNK-transfected cells, supporting the conclusion that Figure 8 JNK overexpression inhibits AIG and IGF-I stimulated AIG. Parental MCF-7 cells and stable Wt and Mt JNK transfectant MCF-7 cells were suspended in 5% CSS and 0.8% Seaplaque agarose. Cells were seeded at 30 000 per dish and grown for 9 days. IGF-I (50 ng/ml) was added as indicated. Each sample was grown in triplicate and colonies were counted within the same surface area IGF-I-mediated phosphorylation of Ser 312 is PI 3-kinase dependent. Further, we assessed the potential role of JNK activity on tyrosine phosphorylation of IRS-1. Immunoprecipitates of total IRS-1 were analysed for tyrosine phosphorylation by Western blot analysis using an antiphosphotyrosine antibody. Tyrosine phosphorylation of IRS-1 was robust after 1 h and somewhat less at 2 h of IGF-I treatment. Cotreatment with the LY294002 did not appear to inhibit tyrosine phosphorylation, but these samples of IRS-1 migrated more rapidly, possibly indicating less serine phosphorylation. Interpretation of IRS-1 tyrosine phosphorylation data using the LY294002 inhibitor is complex, given that it also inhibits Akt. Akt phosphorylates IRS-1 at sites not including Ser 312 however, this serine phosphorylation activity is thought to prevent tyrosine dephosphorylation of IRS-1 (Paz et al., 1999) . Finally, Wt JNK transfectant cells had slightly less tyrosine phosphorylation compared to MCF-7 cells. With these considerations in mind, our data support the conclusion that IGF-I-activated JNK may result in serine phosphorylation of IRS-1, but it is unclear if this action results in an inhibitory tyrosine phosphorylation effect on IRS-1 and its ability to mediate IGF-I signaling in breast cancer cells.
Discussion
In this paper, we demonstrate that IGF-I has potent effects on JNK and Akt activity. IGF-I activation of both PI 3-kinase and Akt supports the hypothesis that this pathway is essential for IGF-I-mediated chemoprotection. These data, along with apoptosis experiments using Wt and Mt Akt transfectants, further confirm our previous results showing that pharmacologic inhibition of PI 3-kinase and its downstream kinases enhanced both doxorubicin-and Taxol-induced apoptosis (Gooch et al., 1999) . Additionally, use of a myr-Akt construct confirmed that enhanced Akt activity has a strong cell survival effect. Figure 9 IGF-I and Taxol treatments lead to Ser 312 phosphorylation of IRS-1 and IGF-I effects were blocked by PI 3-kinase inhibition. MCF-7 cells were plated overnight, then serum-starved. Some samples were pretreated with LY294002 100 mm for 40 min, as indicated. Cells were treated with IGF-I (50 ng/ml) or Taxol (0.25 mm) for the duration of the time indicated. All cells were lysed at the indicated times, lysates were cleared, and IRS-1 was immunoprecipitated using a total IRS-1 antibody. Ser 312 phosphorylation was measured using a rat Ser 307 -specific antibody, which specifically cross-reacts with human phosphoserine 312. The large degree of JNK activation by IGF-I was somewhat surprising since activation of other tyrosine kinase receptors does not typically induce JNK to the same level or time to maximal stimulation as we observed (Kyriakas et al., 1994; Westwick et al., 1994; Fanger et al., 1997; Goedert et al., 1997; Alblas et al., 1998) . For example, other investigators (Miller et al., 1996; Desbois-Mouthon et al., 1998) have reported that insulin treatment of CHO or Rat 1 HIR fibroblasts activates JNK within 10-15 min of exposure. This activity results in an increase in AP-1 DNA binding and possibly cell proliferation (Miller et al., 1996) . Given that IGF-I induction of JNK is notably higher than what has been reported with other growth factors and since other growth factors induce proliferation through JNK (Bost et al., 1997) , we were initially perplexed by our results showing a lack of IGF-I proliferative (data not shown) or survival responses through JNK.
Activated PI 3-kinase has previously been shown to be upstream of JNK after exposure to other growth factors like platelet-derived growth factor (PDGF), and in some cases EGF, but not after exposure to UV irradiation or osmotic shock (Logan et al., 1997; LopezIlasaca et al., 1997) . Other investigators report that despite IGF-I's limited ability to induce JNK in embryonic kidney 293 cells, pretreatment with IGF-I suppresses JNK stimulation by TNFa and anisomycin (Okubo et al., 1998) . These investigators stressed the necessity of IGF-I pretreatment in order to observe inhibition of JNK in response to cellular stress; however, we did not study the effects of IGF-I pretreatment in our model. Also, these investigators did not study JNK response to IGF-I treatment alone beyond 1 h of exposure. In our model, we observed maximal activity after 2 h of IGF-I exposure. Given these mixed results reported by others, we initially anticipated that if IGF-I had any measurable effect on JNK it might be to abrogate chemotherapy induction of JNK. It is now clear that although chemotherapy drugs activate JNK, IGF-I induced JNK to a far greater extent in our breast cancer model. Cotreatment with chemotherapy and IGF-I further enhanced JNK activity, despite their opposing effects on cell survival.
The biological effect of overexpressed JNK suggests that even though it was induced both by Taxol and IGF-I, JNK's primary effect appears to be proapoptotic rather than protective. More so, IGF-I lost its cytoprotective effect in cells overexpressing JNK, where the stoichiometry of JNK versus Akt protein levels may have allowed JNK-induced apoptotic response to overcome some of the IGF-I-mediated Akt effects in these cells. Further, we show that JNK activity inhibited IGF-I responses, in the absence of stress, by reducing colony formation in the AIG assay and inhibiting the IGF-Imediated increase in colony growth. Thus, we turned our attention to potential mechanisms of inhibition of IGF-IR signaling.
Much attention has recently been drawn to IRS phosphorylation of serine residues that may result in feedback inhibition of IR and IGF-IR downstream signaling or insulin resistance in diabetic models. Predictors of such biological responses focus on both the inhibition of IRS tyrosine-phosphorylation and the ability of serine-phosphorylated IRS proteins to bind and become phosphorylated by IR. Ser 307 of IRS-1 has become particularly interesting since it lies adjacent to the protein tyrosine binding (PTB) domain, the region required for receptor binding (Aguirre et al., 2002) . In diabetic models, JNK (activated by TNFa-, anisomysin-, and PI 3-kinase-sensitive kinases) phosphorylates this site to inhibit IRS downstream signaling (Rui et al., 2001) . In contrast, the PI 3-kinase-sensitive kinase, Akt, has four consensus serine phosphorylation motifs in IRS-1, not including Ser 307 , which when phosphorylated inhibits tyrosine dephosphorylation of IRS-1 resulting in prolonged IRS-1-mediated responses (Paz et al., 1999) . The region containing Ser 307 also does not appear to be a phosphorylation motif for other kinases reported to phosphorylate IRS-1, including MAPK and PI 3-kinase (De Fea and Roth, 1997) . Further, the stress kinase p38 is an unlikely candidate in our model since IGF-I treatment does not enhance its activity in MCF-7 cells (data not shown). Interestingly, Rui et al. (2001) have predicted that kinases other than just JNK may phosphorylate rat IRS-1 Ser 307 . This conclusion was based on data showing TNFa stimulation of Ser 307 phosphorylation is inhibited by PD98059. Although LY294002 blocked serine phosphorylation, it did not inhibit insulin activation of JNK after a 10 min exposure time. It is unclear if JNK may be activated at later time points in this model. However, since LY294002 cotreatment completely inhibited JNK activation by IGF-I and since IGF-I-mediated Ser 312 phosphorylation in our cells is also mediated by a PI 3-kinase-sensitive kinase, JNK is the most likely sole mediator of this effect. Further, Taxol treatment both activated JNK and enhanced human Ser 312 phosphorylation of IRS-1 in our model. To our knowledge, little is published regarding the subsequent biological effects of growth factor activation of JNK in diabetic or cancer models, particularly looking at the combined effects of growth factors and chemotherapeutic agents in cancer models. These responses may be particularly relevant given that many solid tumors, including breast, prostate, lung, and colon cancer, commonly overexpress IGF-IR. These tumors are also often treated with chemotherapeutic agents. Intuitively, one may anticipate that the serine phosphorylation of downregulatory sites such as Ser 312 of IRS-1 and subsequent tyrosine dephosphorylation may be observed to a much lesser degree in cancer cells compared to normal cells. Our results indicate that phosphorylation of Ser 312 is quite high in cancer cells. On the other hand, we did not observe a very significant decrease in IRS-1 tyrosine-phosphorylation using JNK overexpression approaches. Inhibition of PI 3-kinase in MCF-7 cells and JNK transfectants resulted in faster mobility of tyrosine-phosphorylated IRS-1 indicating a reduction in serine phosphorylation. These data lead to uncertainty as to whether serine phosphorylation of IRS-1 actually inhibits its ability to serve as an IGF-IR substrate in breast cancer cells. We have not yet studied this interaction in our model. Somewhat in contrast to our model, Hemi et al. (2002) report that IRS-1 serine phosphorylation was enhanced by anisomycin, TNFa, and Smase (sphingomyelinse) treatment via phosphorylation of ErbB2 and 3 in Fao hepatoma cells, but that tyrosine phosphorylation of IRS-1 was inhibited by LY294002. Interestingly, JNK activity in response to the above treatments was not assessed in this paper but there data may implicate the complexity of PI 3-kinase signaling through both Akt and JNK (Figure 10 ). These findings also underline the relevance of crosstalk among stress-and growth factor-related pathways that may converge on JNK and may be directly applied to cancer models as a therapeutic target.
Clearly, the biological role(s) of JNK are controversial (see review by Minden and Karin, 1997) . Simple activation of JNK by any agonist does not imply the same biological response. JNK activity may either convey resistance or sensitivity to cellular stress (Fuchs et al., 1998; Okubo et al., 1998) or even proliferative responses (Bost et al., 1997) . Some investigators have begun to study the effects of diverse stimuli on kinases upstream of JNK and differential regulation resulting from the various JNK isoforms derived from the three JNK genes, JNK1, JNK2, and JNK3 (Gupta et al., 1996; Cuenda et al., 1997) in attempts to understand the various biological responses associated with JNK activity. Our findings that IGF-I and stress treatments activate JNK to inhibit IGF-I signaling make JNK an excellent target for cancer treatment. Inducing JNK response may simultaneously enhance the efficacy of radio-and chemotherapy as well as attenuating IGF-IR responses in cancer models. 
